

No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise.

The short form base shelf prospectus dated October 3, 2023, as amended by this amendment, has been filed under legislation in each of the provinces of Canada that permits certain information about these securities to be determined after this short form base shelf prospectus has become final and that permits the omission from this short form base shelf prospectus of that information. The legislation requires the delivery to purchasers of a prospectus supplement containing the omitted information within a specified period of time after agreeing to purchase any of these securities, except in cases where an exemption from such delivery requirement is available.

The amended short form base shelf prospectus is filed in reliance on an exemption from the preliminary base shelf prospectus requirement for a well-known seasoned issuer.

Information has been incorporated by reference in the amended short form base shelf prospectus from documents filed with securities commissions or similar authorities in Canada. Copies of the documents incorporated herein by reference may be obtained on request without charge from the Corporate Secretary of Emera Incorporated, 5151 Terminal Road, Halifax, Nova Scotia, B3J 1A1 (telephone: 902-428-6096) and are also available electronically at www.sedarplus.ca.

The amended short form base shelf prospectus constitutes a public offering of these securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities. The securities offered hereby have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or any state securities laws. Accordingly, the securities offered hereby may not be offered or sold in the United States of America or to or for the account or benefit of U.S. persons (within the meaning of Regulation S under the U.S. Securities Act) except pursuant to an available exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. The amended short form base shelf prospectus does not constitute an offer to sell or a solicitation of an offer to buy any of the securities offered hereby within the United States or to or for the account or benefit of U.S. persons.

**AMENDMENT NO. 1 DATED NOVEMBER 13, 2024 TO THE
SHORT FORM BASE SHELF PROSPECTUS DATED OCTOBER 3, 2023**

New Issue

November 13, 2024



**EMERA INCORPORATED
\$1,000,000,000**

Common Shares

The Short Form Base Shelf Prospectus dated October 3, 2023 (the “**Prospectus**”) of Emera Incorporated (“**Emera**” or the “**Company**”) is hereby amended to increase the aggregate sale price of common shares (“**Common Shares**”) that may be offered from time to time under the Prospectus, as supplemented, from \$600,000,000 to \$1,000,000,000 (or the equivalent in U.S. dollars determined using the daily exchange rate posted by the Bank of Canada on the date the Common Shares are sold). As of the date of this Amendment No. 1, the Company has distributed Common Shares in an aggregate amount of \$582,448,285 under the Prospectus, as supplemented.

Specifically, the Prospectus is amended by deleting the two references to “\$600,000,000” contained on the face page of the Prospectus and substituting \$1,000,000,000 therefor. As a result, the first sentence of the first paragraph of the text on the face page of the Prospectus, as so amended reads as follows:

“Emera Incorporated” (“**Emera**” or the “**Company**”) may from time to time offer common shares (“**Common Shares**”), having an aggregate sale price of up to \$1,000,000,000 (or the equivalent in U.S. dollars determined using the daily exchange rate posted by the Bank of Canada on the date the Common Shares are sold) during the 25 month period ending November 4, 2025 that this short form base shelf prospectus (the “**Prospectus**”), including any amendments hereto, remains valid.”

The Prospectus is amended by deleting the first sentence of the paragraph under the heading “Use of Proceeds” on page 6 of the Prospectus and substituting the following therefor:

“Emera may offer Common Shares from time to time, up to an aggregate sale price of \$1,000,000,000 (or the equivalent in U.S. dollars determined using the daily exchange rate posted by the Bank of Canada on the date the Common Shares are sold) during the 25 month period ending November 4, 2025 that this Prospectus, including any amendments hereto, remains valid.”

The Prospectus must be read together with this amendment, any documents incorporated or deemed to be incorporated by reference therein from time to time and any supplements relating to an offering of Common Shares thereunder. The statements contained in the Prospectus or in a document incorporated or deemed to be incorporated by reference therein on or subsequent to October 3, 2023 are modified or superseded for the purposes of this amendment to the extent that a statement contained in any subsequently filed document, which also is or is deemed to be incorporated by reference therein, modifies or supersedes that statement.

CERTIFICATE OF EMERA INCORPORATED

Dated: November 13, 2024

The short form base shelf prospectus dated October 3, 2023 as amended by this amendment, together with the documents incorporated in the prospectus by reference, will, as of the date of the last supplement to the prospectus relating to the securities offered by the prospectus and the supplement(s), constitute full, true and plain disclosure of all material facts relating to the securities offered by the prospectus and the supplement(s) as required by the securities legislation of each of the provinces of Canada.

(signed) "*Scott C Balfour*"
Scott C. Balfour
President and Chief Executive Officer

(signed) "*Gregory W. Blunden*"
Gregory W. Blunden
Chief Financial Officer

On behalf of the Board of Directors

(signed) "*M. Jacqueline Sheppard*"
M. Jacqueline Sheppard
Director

(signed) "*Kent M. Harvey*"
Kent M. Harvey
Director

